- Prothena has developed broad expertise in removing plaques across different pathologies.
- FDA's acceptance of amyloid plaque reduction as a sufficient secondary endpoint for an accelerated approval de-risks multiple smallcap biotechs and provides Prothena with a clear regulatory pathway.
- Prothena's therapeutics for Parkinson's (Ph 2) and Alzheimer's (Ph 1) are differentiated and best-in-class antibodies.
- Roche and Bristol Myers have collaborations with Prothena for the Parkinson's and Alzheimer's treatments, respectively.
- Continued strong data can potentially lead to an acquisition in 6 to 12 months.
For further details see:
Prothena: Well-Positioned In Parkinson's And Alzheimer's